Funding profile · Proteomics research tools

Correlia Biosystems

Two Form D filings, $10.83 million sold, and a $7 million Series A announcement the filing does not match. The 2020 round was filed five weeks before it was announced and was $2.57 million larger on paper.

$10.83MTotal equity reported sold across two Form D filings
$9.57MSold at the Oct 2020 filing, against $7.0M announced
$1.25MSold of $3.25M offered, May 2023 filing, 2 investors
$824KFederal SBIR grants on record, 7% of filed equity

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2014 to 2016 Federal SBIR grants $823,898 NSF SBIR Phase I; NIH NHLBI and NIDDK R43 NSF, NIH
Through Mar 2020 Angel, seed, accelerator $2.6M stated Not itemized. Y Combinator, QB3 and Blue Bear Ventures named elsewhere Founder interview
Oct 2020 Equity offering, first sale Oct 2, 2020 $9,574,826 offered and sold 41 investors Form D
Nov 2020 Announced as Series A $7.0M Neotribe Ventures (lead), Cota Capital, the Regents of the University of California, and others Company release
May 2023 Equity and other, first sale May 1, 2023 $1,254,212 sold of $3,250,000 2 investors Form D
After May 2023 No further filing None None Nothing found

What the filings show

Correlia Biosystems, Inc. · Form D · filed Oct 16, 2020

First sale
Oct 2, 2020
Offered
$9,574,826 equity
Sold
$9,574,826 · $0 remaining
Investors
41 · average about $233,532
Exemption
Rule 506(b)
Issuer
Delaware corporation, Berkeley, CA · industry listed as Biotechnology
Related persons
Akwasi Apori (executive officer, director); Samuel Tia (director)
Filing
SEC EDGAR, CIK 0001827990

Correlia Biosystems, Inc. · Form D · filed May 9, 2023

First sale
May 1, 2023
Offered
$3,250,000 equity and other securities
Sold
$1,254,212 · $1,995,788 remaining
Investors
2 · average about $627,106
Exemption
Rule 506(b)
Minimum investment
$0 · no non-accredited investors
Related persons
Akwasi Apori (executive officer, director); Kursad Araz (director); Kittu Kolluri (director)
Filing
SEC EDGAR, CIK 0001827990

Reading the filings

  1. The filing came first, and it was bigger.The Form D was filed on October 16, 2020 with a first sale of October 2. The press release went out on November 20, thirty five days later, and called the round $7 million. The filing reports $9,574,826 sold, a difference of $2,574,826. An offering sized to exactly the amount already sold, with a first sale weeks before the announcement, is the shape a round takes when earlier instruments convert into it. Nothing in the filings says so, and no amendment explains the gap.
  2. Forty one checks became two.$9,574,826 across 41 investors is about $233,532 each, which reads as a priced round with a lead plus a long tail of angels. In May 2023, $1,254,212 across 2 investors is about $627,106 each. The average check roughly tripled while the investor count fell by 39. Two investors is the signature of an insider round.
  3. The 2023 round was never announced and never closed out on the record.It offered $3,250,000 and reported $1,254,212 sold, leaving $1,995,788 unsold at filing. No amended Form D has appeared in the three years since, and no press release was found. Regulation D requires the initial notice within 15 days of first sale but no progress updates, so the silence proves nothing either way.
  4. The board seat announced in 2020 first appears in a filing in 2023.The November 2020 release said Neotribe was joining the board. The Form D filed a month earlier lists only Akwasi Apori and co-founder Samuel Tia. Kittu Kolluri, Neotribe’s founder, shows up as a director on the May 2023 filing, alongside co-founder Kursad Araz. Samuel Tia is absent from the 2023 filing, though he was still presenting the company’s work at a conference in May 2024.
  5. Grants are a small slice here, which is unusual for a Berkeley hardware spinout.$823,898 of NIH and NSF SBIR money against $10,829,038 of filed equity is about 7 percent. For most preclinical device and diagnostics companies the ratio runs the other way. Correlia raised its non-dilutive money in 2014 to 2016 and has no federal award on record since.
  6. No vehicles, no syndicates, no second issuer.An EDGAR full text search returned only the company’s own two filings under CIK 0001827990. No SPV or fund named after Correlia appears, and there is no name collision to disentangle. Both filings are direct issuer offerings under Rule 506(b).

Commercial signals

Signal Detail Source type
Product PIXI automated immunoassay platform. Early access announced April 2023, on the market that year. Runs on third party liquid handlers. Trade press
Regulatory No FDA 510(k), PMA or De Novo record and no registered clinical trial. Sold for research use. Public record
Customers No pharma customer has ever been named by the company. An investor blog names Amgen as the first pilot contract. The pharma claim itself varies across sources between the top 10, top 15 and top 20 by size. Claims differ
Validation No peer-reviewed publication. One 2024 AAPS conference poster, co-authored by two Correlia employees with a contract lab. Thin
IP No patent found under the company name. The core invention is a UC Berkeley Herr lab technique, apparently licensed. The Regents are also on the cap table as a 2020 Series A investor. Public record
Operating status Website live and unchanged on September 23, 2026, with Internet Archive captures in February, March and July 2026. LinkedIn lists 11 to 50 employees. Newest dated company news: June 1, 2024. Public record

What to watch

  • A third Form D, or an amendment closing out the $1,995,788 left unsold in May 2023.
  • Whether the next filing still lists two investors, and whether any new director appears.
  • Any disclosure of placements, revenue or a named customer.
  • A peer-reviewed validation, which would move this from a tools story to a platform story.
  • Further federal awards; none on record since 2016.

The Correlia Biosystems story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • BillionToOne: Shared investor: Neotribe Ventures. A Menlo Park laboratory that counts individual DNA molecules in blood, first to tell a pregnant patient whether her fetus is at risk for a recessive disease, now to read
  • Moichor: Shared investor: Neotribe Ventures. An AI-assisted animal blood and cytology lab that started with birds and reptiles and now sells an in-clinic analyzer for dogs and cats
  • Known Medicine: Shared investor: Cota Capital. A Salt Lake City company that grew hundreds of micro-tumors from one patient sample and dosed each, to tell an oncologist what would work
  • InnaMed: Also in Diagnostics. A Philadelphia startup that built a microneedle, cartridge-based blood testing platform called HomeLab, sold multi-year testing services to pharmaceutical companies, and

Sources

  1. Public recordForm D, Correlia Biosystems, Inc., accession 0001827990-20-000001SEC · Oct 16, 2020
  2. Public recordForm D, Correlia Biosystems, Inc., accession 0001827990-23-000001SEC · May 9, 2023
  3. Public recordNIH RePORTER, R43HL123846 and R43DK109863NIH · FY2014 to FY2016
  4. Public recordNSF SBIR Phase I award 1416633NSF · 2014
  5. Public recordCorrelia Biosystems, Inc. company recordUC Berkeley IPIRA · accessed Sep 2026
  6. IndependentCorrelia Biosystems Closes $7M Series A RoundGenomeWeb · Nov 23, 2020
  7. IndependentCorrelia Biosystems nabs $7 million in series A financingBioWorld · 2020
  8. IndependentCorrelia Launches PIXI ELISA PlatformClinical Lab Products · Apr 19, 2023
  9. Interview7 Questions for Correlia Biosystems Co-Founder Akwasi AporiCITRIS and the Banatao Institute · Mar 10, 2020
  10. ConferenceEvaluating the PIXI Platform, poster T1330-02-10AAPS National Biotechnology Conference · May 14, 2024
  11. CompanyCorrelia Biosystems Closes $7M Series A to Enable Product LaunchPR Newswire · Nov 20, 2020
  12. InvestorBBV Founder Spotlight: Correlia BiosystemsBlue Bear Ventures · 2022
  13. CompanyCorrelia home, product and news pagescorreliabio.com · accessed Sep 23, 2026

Compiled from SEC, NIH, NSF and other public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Correlia Biosystems. This page is not an offer to sell or a recommendation to buy any security.